The Effect of Boswellia Serrata Extract on Osteoarthritis

The Effect of a formulation containing Boswellia Serrata extract on the Osteoarthritis patients’ pain alleviation and quality of life improvement and comparison with Placebo and Piroxicam Gel

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190107042264N1

Enrollment

Registered

2019-03-05

Start date

2019-02-20

Completion date

Unknown

Last updated

2019-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis. Osteoarthritis of knee

Interventions

Intervention 1: Intervention group: Herbal Cream containing Boswellia Serrata Extract, Produced in Ahvaz Jundishapur University of Medical Sciences

3 times a day for 4 weeks. Intervention 2: Control group: Placebo cream, Produced in Ahvaz Jundishapur University of Medical Sciences, 3 times a day for 4 weeks. Intervention 3: Control group: Piroxic

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patient's presenting with knee pain with Osteoarthritis as a diagnosis at least three months since diagnosis Visual Analog Scale score must be more than 40 after stopping the treatment for 7 days Lequesne functional Index more than 7 after stopping the treatment for 7 days Patients must have the ability to stand and walk and to provide written and oral consent

Exclusion criteria

Exclusion criteria: Allergy of any kind to Boswellia and any of it's derivatives Malignancy Patient's unresponsive to conventional treatment Inflammatory Arthropathies Hyperuricemia Surgery planned New injury in sight of OA Intraarticular corticosteroid injection in the past 3 months Liver or Renal Failure History of gastric ulceration Uncontrolled Hypertension Congestive Heart Failure Pregnancy

Design outcomes

Primary

Measure	Time frame
Stiffness of the Joint. Timepoint: The beginning of the study, 7, 14, 28 days after start of drug use. Method of measurement: The Western Ontario and McMaster Universities Osteoarthritis Index.;Joint function. Timepoint: The beginning of the study, 7, 14, 28 days after start of drug use. Method of measurement: The Western Ontario and McMaster Universities Osteoarthritis Index; Lequesne Functional Index.;Pain. Timepoint: The beginning of the study, 7, 14, 28 days after start of drug use. Method of measurement: The Western Ontario and McMaster Universities Osteoarthritis Index; Visual Analog Scale.;Improvement in Quality of Life. Timepoint: The end of the study. Method of measurement: Summation and Analysis of The Western Ontario and McMaster Universities Osteoarthritis Index and Visual Analog Scale.	—

Measure

Time frame

Stiffness of the Joint. Timepoint: The beginning of the study, 7, 14, 28 days after start of drug use. Method of measurement: The Western Ontario and McMaster Universities Osteoarthritis Index.;Joint function. Timepoint: The beginning of the study, 7, 14, 28 days after start of drug use. Method of measurement: The Western Ontario and McMaster Universities Osteoarthritis Index; Lequesne Functional Index.;Pain. Timepoint: The beginning of the study, 7, 14, 28 days after start of drug use. Method of measurement: The Western Ontario and McMaster Universities Osteoarthritis Index; Visual Analog Scale.;Improvement in Quality of Life. Timepoint: The end of the study. Method of measurement: Summation and Analysis of The Western Ontario and McMaster Universities Osteoarthritis Index and Visual Analog Scale.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactKarim Mowla

Ahvaz University of Medical Sciences

mowla-k@ajums.ac.ir+98 61 3374 3001

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026